2022
Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery
Petersen G, Bousabarah K, Verma T, von Reppert M, Jekel L, Gordem A, Jang B, Merkaj S, Fadel S, Owens R, Omuro A, Chiang V, Ikuta I, Lin M, Aboian MS. Real-time PACS-integrated longitudinal brain metastasis tracking tool provides comprehensive assessment of treatment response to radiosurgery. Neuro-Oncology Advances 2022, 4: vdac116. PMID: 36043121, PMCID: PMC9412827, DOI: 10.1093/noajnl/vdac116.Peer-Reviewed Original ResearchGamma KnifeTreatment responseBrain metastasis patientsFurther treatment planningNumber of lesionsMean followBrain metastasesMetastasis patientsMultiple lesionsDiagnostic followSingle patientStereotactic radiosurgeryPatientsLesionsIndividual lesionsPrevalenceAccurate surveillanceHeterogenous responseTreatment planningTreatmentFollowRadiosurgerySize assessmentComprehensive assessmentResponse
2019
Sequencing and curation strategies for identifying candidate glioblastoma treatments
Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB. Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics 2019, 12: 56. PMID: 31023376, PMCID: PMC6485090, DOI: 10.1186/s12920-019-0500-0.Peer-Reviewed Original ResearchConceptsPotential treatment optionClinical research studiesWhole-genome sequencingPharmacologic interventionsCancer patientsTreatment optionsClinical resultsPatientsConclusionThese resultsGlioblastoma treatmentPotential cancer treatmentPanel sequencingActionable variantsCancer treatmentGlioblastoma tumorsSame variantSequencing assaysDrug targetsRNA sequencingRNA-seqTreatmentNew York CitySequencingTumorsClinicians
2013
Bevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdema
2007
Dynamic history of low‐grade gliomas before and after temozolomide treatment
Ricard D, Kaloshi G, Amiel‐Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle‐Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang‐Xuan K, Delattre J. Dynamic history of low‐grade gliomas before and after temozolomide treatment. Annals Of Neurology 2007, 61: 484-490. PMID: 17469128, DOI: 10.1002/ana.21125.Peer-Reviewed Original ResearchConceptsMean tumor diameterLow-grade gliomasMajority of tumorsTemozolomide treatmentImpact of temozolomideSerial magnetic resonance imagesUntreated low-grade gliomaGenetic alterationsNeoadjuvant temozolomideTumor diameterContinuous administrationP53 overexpressionOptimal durationTumor progressionTumorsTemozolomidePatientsGliomasMagnetic resonance imagesNatural progressionTreatmentProgressive growthLower ratesResonance imagesP53